GB:0H19 Stock Latest News
Company AnnouncementsOrexo Wins FDA Review of High‑Dose Naloxone Nasal Powder IZIPRY3d ago
Company AnnouncementsOrexo AB Earnings Call: Pipeline Progress Amid Strain1w ago
Company AnnouncementsOrexo Deepens R&D-Driven Transformation Amid Losses and Capital Raise1w ago
Pre-EarningsORXOF Upcoming Earnings Report: What to Expect?1w ago
Company AnnouncementsOrexo to Present Q3 2026 Interim Results in Live Investor Call2w ago
Company AnnouncementsOrexo’s AmorphOX® tech shows promising oral semaglutide bioavailability2w agoCompany AnnouncementsOrexo launches 250 MSEK rights issue to fund pipeline and strengthen finances3w ago
Company AnnouncementsOrexo Resubmits High-Dose Opioid Overdose Rescue Drug IZIPRY for FDA Review1M ago
Company AnnouncementsOrexo Wins FDA Green Light to Advance Needle‑Free Anaphylaxis Treatment OX6401M ago
Company AnnouncementsOrexo Wins BARDA Funding Boost to Extend OX390 Overdose Rescue Development1M ago- Company AnnouncementsOrexo CFO Fredrik Järrsten to Step Down as Company Streamlines Operations2M ago
Company AnnouncementsOrexo Moves to Settle U.S. DOJ Probe With Non‑Prosecution Deal2M ago
Company AnnouncementsOrexo strengthens partnership strategy with new business development chief4M ago
Company AnnouncementsOrexo posts positive in‑vivo data for nasal overdose reversal candidate OX3905M ago- Company AnnouncementsOrexo AGM Backs Board, Expands Capital Flexibility and Incentive Plans5M ago
Company AnnouncementsOrexo Deepens R&D Push as Losses Widen and Bond Redeemed Early6M ago
Company AnnouncementsOrexo updates share and voting structure after class C conversion7M agoCompany AnnouncementsOrexo Calls 2026 AGM to Decide on Governance, Capital Measures and Incentive Plan7M ago
Company AnnouncementsOrexo Publishes 2025 Annual and Sustainability Reports Detailing Strategy and Market Position7M ago